ストックスクリーナーアプリを入手
74.52
0.05%
0.04
プレマーケット:
75.66
1.14
+1.53%
前日終値:
$74.48
開ける：
$74.48
24時間の取引高:
3.03M
Relative Volume:
0.99
時価総額：
$14.60B
収益：
$579.96M
当期純損益:
$-729.89M
株価収益率:
-19.89
EPS:
-3.7459
ネットキャッシュフロー:
$-452.02M
1週間 パフォーマンス:
+7.44%
1か月 パフォーマンス:
+14.01%
6か月 パフォーマンス:
-2.58%
1年 パフォーマンス:
+74.19%
1日の値動き範囲:
$73.56
$75.28
1週間の範囲:
$68.82
$75.28
52週間の値動き範囲:
$42.09
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
74.52 | 14.59B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-03-10 | 開始されました | William Blair | Outperform |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-11 | 開始されました | Bernstein | Outperform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026 - Legal Desire Media and Insights
BridgeBio lands $1 billion, mostly from S.F.'s Sixth Street, with three late-stage drugs in hand - The Business Journals
BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal - Moomoo
BridgeBio raises $1 billion in preferred equity - The Pharma Letter
BridgeBio secures up to $1B in preferred equity - MSN
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - Sixth Street
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street - MSN
BridgeBio secures $1 billion in convertible preferred equity - Investing.com
BridgeBio gets $1B from Sixth Street, HCRx for three launches - Stock Titan
Global private equity giants continue to increase investments in the innovative pharmaceuticals sector, with firms including KKR injecting $1 billion into BridgeBio. - Moomoo
Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity - 富途牛牛
Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity - Bloomberg.com
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Index - marketscreener.com
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO) - Seeking Alpha
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark - marketscreener.com
Sector Update: Healthcare - Moomoo
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial - Moomoo
BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline - DirectorsTalk Interviews
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Growth Benchmark - marketscreener.com
BridgeBio (BBIO) Reports Positive Phase 3 Results for Infigratin - GuruFocus
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - The Manila Times
BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia - Quiver Quantitative
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
BridgeBio Pharma, Inc. Actuals & Estimates (NASDAQ:BBIO) - TradingView
BridgeBio shareholders approve board changes and equity plan - The Globe and Mail
BBIO Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma Adopts Third Amended 2021 Stock Option and Incentive Plan Following Shareholder Approval - Minichart
BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares - Stock Titan
2CL Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma, Inc. Actuals & Estimates (MUN:2CL) - TradingView
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – LS:A2PLX7 - TradingView
Price to book forward of BridgeBio Pharma, Inc. – LS:A2PLX7 - TradingView
Price to book forward of BridgeBio Pharma, Inc. – GETTEX:2CL - TradingView
Enterprise value to EBITDA forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Price to sales forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Enterprise value to EBIT forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
BridgeBio Pharma Insider Sold Shares Worth $2,752,270, According to a Recent SEC Filing - marketscreener.com
Price to earnings forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
BridgeBio Pharma director Valantine sells $341,523 in shares By Investing.com - Investing.com Australia
BridgeBio Pharma director Valantine sells $341,523 in shares - Investing.com UK
Understanding the Setup: (BBIO) and Scalable Risk - Stock Traders Daily
Form 4 BridgeBio Pharma Inc For: 24 June By Investing.com - Investing.com Australia
BridgeBio Pharma director Jennifer Cook sells $2.75m in stock. By Investing.com - Investing.com Nigeria
BridgeBio Pharma director Jennifer Cook sells $2.75m in stock. - Investing.com
BridgeBio Pharma (BBIO) director sells stock, exercises options and receives RSUs - Stock Titan
BridgeBio (NASDAQ: BBIO) director receives new RSU and stock option awards - Stock Titan
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.52%
大文字化:
|
ボリューム (24 時間):